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We appreciate the interest of Professors Urbina and McKer-row in our recent paper (1) and welcome the opportunity to
discuss the work further. In our study, we found that benznidazole
consistently cured both acute and chronic Trypanosoma cruzi in-
fections in mice, whereas posaconazole was much less effective,
data consistent with the results of a recent clinical trial (2).
In response to specific comments by our colleagues, we point
out the following. (i) Contrary to what is stated in the letter from
Professors Urbina and McKerrow, our paper does not include
experiments where mice in the acute stage of T. cruzi infection
were treated with benznidazole for 5 or 10 days. (ii) Previous stud-
ies on the efficacy of 20 days of benznidazole treatment against
infections with the T. cruzi CL strain (see references 7 to 10 in the
letter from Professors Urbina and McKerrow) have produced a
range of results, which may reflect the differing mouse models,
timing of treatment start points, and choice of drug vehicle. In-
deed, we notice in a paper by Professor Urbina that treatment of
Swiss mice with 100 mg/kg orally for 20 days resulted in a 100%
cure (see Table 1 in reference 8 of the letter from Professors Ur-
bina and McKerrow). (iii) The bioluminescent CL clone used in
our study was not “hypersusceptible to benznidazole.” We would
have been careless not to test for this. The 50% inhibitory concen-
tration for intracellular amastigote forms was 1.2 M (unpub-
lished data), not significantly different from that for the wild type
and well within the normal range reported elsewhere for T. cruzi
CL and other diverse strains (3). (iv) Our treatment data are con-
sistent with findings reported in a recent paper (4). Using PCR to
assess drug efficacy, these authors find that treatment of T. cruzi
CL-infected mice with 100 mg/kg benznidazole for 20 days results
in a complete cure. Furthermore, they also find that posaconazole
has a limited curative effect, even when treatment is extended to
40 days.
Investigating whether subcurative treatment with posacona-
zole leads to improved clinical outcomes is a complex issue and
was not an objective of our study. However, it is unlikely that any
new treatment for T. cruzi infection will be licensed unless it can
achieve a sterile cure. Unfortunately, based on in vitro studies (3),
in vivo assessment (1, 4), and a clinical trial (2), posaconazole does
not seem to meet this benchmark.
As outlined by Professors Urbina and McKerrow, benznida-
zole is far from an ideal drug and the search for more effective
alternatives must remain a research priority.
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